Ionis Q4 revenue $325M, up 114%; WAINUA approved; 2024 guidance: revenue >$575M

IONIS PHARMACEUTICALS INC

2023-FY EPS reported -$2.56 revenue$324,505,000

Q4 total revenue $325M (up 114% YoY); full year revenue $788M (up 34%); Q4 operating loss narrowed to $6M from $208M.
WAINUA (eplontersen) FDA-approved for ATTRv-PN; U.S. launch underway; $50M milestone from AstraZeneca.
Positive Phase 3 data for olezarsen (FCS) and donidalorsen (HAE); preparing regulatory submissions.
2024 guidance: revenue >$575M, non-GAAP operating loss <$475M, cash ~$1.7B.
SPINRAZA royalties $240M in 2023; QALSODY royalties included; pipeline milestones with bepirovirsen, ION582.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.